Armistice Capital LLC Has $12.51 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Armistice Capital LLC lifted its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 32.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500,000 shares of the company’s stock after acquiring an additional 122,000 shares during the quarter. Armistice Capital LLC owned approximately 0.37% of Centessa Pharmaceuticals worth $12,505,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of CNTA. Millennium Management LLC lifted its holdings in Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after buying an additional 210,737 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at $2,176,000. Geode Capital Management LLC increased its position in shares of Centessa Pharmaceuticals by 44.7% in the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock valued at $1,149,000 after buying an additional 26,994 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Centessa Pharmaceuticals by 155.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock worth $5,630,000 after purchasing an additional 260,702 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Centessa Pharmaceuticals by 29.2% during the 2nd quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock worth $1,291,000 after purchasing an additional 22,205 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CNTA shares. Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their target price for the company from $36.00 to $40.00 in a research note on Wednesday, April 1st. B. Riley Financial downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $35.00 to $42.00 in a report on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA opened at $39.87 on Thursday. The firm’s fifty day moving average price is $39.65 and its two-hundred day moving average price is $31.11. The stock has a market cap of $6.17 billion, a PE ratio of -22.27 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $12.30 and a fifty-two week high of $40.26. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, equities analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 41,076 shares of the business’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. The trade was a 39.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.09% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.